When did Zevra Therapeutics, Inc. report Q4 2024 earnings?

Zevra Therapeutics, Inc. (ZVRA) reported Q4 2024 earnings on March 11, 2025 after market close.

What were Zevra Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Zevra Therapeutics, Inc. reported revenue of $12.0M and eps of $-0.67 for Q4 2024.

Did Zevra Therapeutics, Inc. beat estimates in Q4 2024?

Revenue missed the consensus estimate of $16.7M by $4.6M. EPS missed the consensus estimate of $-0.39 by $0.28.

Where can I find Zevra Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001437749-25-007320) directly on SEC EDGAR. The filing index links above go to sec.gov.

Zevra Therapeutics, Inc. ZVRA Q4 2024 Annual earnings

Reported March 11, 2025 · After market close

Revenue$12.0MMiss by $4.6M

EPS-$0.67Miss by $0.28

Revenue estimate$16.7M

EPS estimate-$0.39

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$33.9M

EPS estimate$0.08

Financials

Q4 2024

Income statement

See full

Revenue$12.0M-6.8%

Gross profit$10.7M-2.2%

Operating income-$15.4M-1.7%

Net income-$35.7M-79.7%

EPS (diluted)-$0.69—

Balance sheet

See full

Cash & equivalents$33.8M-21.5%

Total debt$60.3M+894%

Total equity$39.7M-35.9%

Total assets$178.1M+3.4%

Cash flow

See full

Operating cash flow-$16.3M-0.6%

CapEx--100%

Free cash flow-$16.3M-0.1%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$445.16M+79.3%

Enterprise value$471.67M+123%

P/S18.9×+9.8×

Profitability

See full

Gross margin68.6%-20.7pp

Operating margin-368.5%-9,612pp

Net margin-446.9%-1,119pp

FCF margin-295%-1,042pp

Returns & leverage

See full

Return on equity-207.8%-398pp

Debt / equity1.5×+1.4×

Current ratio2.5×+1.3×

Segments

By product

See full

MIPLYFFA$2.5M—

OLPRUVA$100.0K—

By segment

See full

Reportable Segment$12.0M—

Versus estimates

Revenue

Q1 2026$36.2MBeat by $4.3M Q4 2025$34.1MBeat by $6.0M Q3 2025$26.1MMiss by $578.9K Q2 2025$25.9MBeat by $1.4M Q1 2025$20.4MMiss by $672.6K

Q4 2024$12.0MMiss by $4.6M

Diluted EPS

Q1 2026$0.18Beat by $0.12 Q4 2025$1.16Beat by $1.11 Q3 2025-$0.01Beat by $0.01 Q2 2025$1.21Miss by $0.98 Q1 2025-$0.06Beat by $0.15

Q4 2024-$0.67Miss by $0.28

Ask the moment Zevra Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Zevra Therapeutics, Inc. report Q4 2024 earnings?: Zevra Therapeutics, Inc. (ZVRA) reported Q4 2024 earnings on March 11, 2025 after market close.
What were Zevra Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Zevra Therapeutics, Inc. reported revenue of $12.0M and eps of $-0.67 for Q4 2024.
Did Zevra Therapeutics, Inc. beat estimates in Q4 2024?: Revenue missed the consensus estimate of $16.7M by $4.6M. EPS missed the consensus estimate of $-0.39 by $0.28.
Where can I find Zevra Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001437749-25-007320) directly on SEC EDGAR. The filing index links above go to sec.gov.